| 10 years into the resurgence of covalent drugs E De Vita Future Medicinal Chemistry 13 (2), 193-210, 2021 | 90 | 2021 |
| Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry R Longuespée, AK Wefers, E De Vita, AK Miller, DE Reuss, W Wick, ... Acta neuropathologica communications 6, 1-9, 2018 | 40 | 2018 |
| Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs) Q Zhang, CS Kounde, M Mondal, JL Greenfield, JR Baker, S Kotelnikov, ... Chemical Communications 58 (78), 10933-10936, 2022 | 31 | 2022 |
| PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs M Maneiro, E De Vita, D Conole, CS Kounde, Q Zhang, EW Tate Progress in medicinal chemistry 60, 67-190, 2021 | 31 | 2021 |
| A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering A Sananes, I Cohen, A Shahar, A Hockla, E De Vita, AK Miller, ... Journal of Biological Chemistry 293 (33), 12663-12680, 2018 | 30 | 2018 |
| Depsipeptides featuring a neutral P1 are potent inhibitors of kallikrein-related peptidase 6 with on-target cellular activity E De Vita, P Schüler, S Lovell, J Lohbeck, S Kullmann, E Rabinovich, ... Journal of medicinal chemistry 61 (19), 8859-8874, 2018 | 29 | 2018 |
| A suite of activity-based probes to dissect the KLK activome in drug-resistant prostate cancer S Lovell, L Zhang, T Kryza, A Neodo, N Bock, E De Vita, ED Williams, ... Journal of the American Chemical Society 143 (23), 8911-8924, 2021 | 23 | 2021 |
| Synthesis and Structure‐Activity Relationships of N‐(4‐Benzamidino)‐Oxazolidinones: Potent and Selective Inhibitors of Kallikrein‐Related Peptidase 6 E De Vita, N Smits, H van den Hurk, EM Beck, J Hewitt, G Baillie, ... ChemMedChem 15 (1), 79-95, 2020 | 20 | 2020 |
| Blocking Kallikrein 6 promotes developmental myelination H Yoon, EM Triplet, WL Simon, CI Choi, LS Kleppe, E De Vita, AK Miller, ... Glia 70 (3), 430-450, 2022 | 14 | 2022 |
| Structure-guided design and optimization of covalent VHL-targeted sulfonyl fluoride PROTACs RR Shah, E De Vita, PS Sathyamurthi, D Conole, X Zhang, E Fellows, ... Journal of Medicinal Chemistry 67 (6), 4641-4654, 2024 | 12 | 2024 |
| Beyond targeted protein degradation: LD· ATTECs clear cellular lipid droplets E De Vita, D Lucy, EW Tate Cell Research 31 (9), 945-946, 2021 | 10 | 2021 |
| A KLK6 activity-based probe reveals a role for KLK6 activity in pancreatic cancer cell invasion L Zhang, S Lovell, E De Vita, PKA Jagtap, D Lucy, A Goya Grocin, S Kjær, ... Journal of the American Chemical Society 144 (49), 22493-22504, 2022 | 9 | 2022 |
| Identification of the first structurally validated covalent ligands of the small GTPase RAB27A M Jamshidiha, T Lanyon-Hogg, CL Sutherell, GB Craven, M Tersa, ... RSC Medicinal Chemistry 13 (2), 150-155, 2022 | 8 | 2022 |
| Development of a fluorogenic ADAMTS-7 substrate S Santamaria, F Buemi, E Nuti, D Cuffaro, E De Vita, T Tuccinardi, ... Journal of enzyme inhibition and medicinal chemistry 36 (1), 2160-2169, 2021 | 6 | 2021 |
| The missing link between (un) druggable and degradable KRAS E De Vita, M Maneiro, EW Tate ACS Central Science 6 (8), 1281-1284, 2020 | 5 | 2020 |
| Design and Synthesis of Ionic Liquid‐Based Matrix Metalloproteinase Inhibitors (MMPIs): A Simple Approach to Increase Hydrophilicity and to Develop MMPI‐Coated Gold Nanoparticles F D'Andrea, E Nuti, S Becherini, D Cuffaro, E Husanu, C Camodeca, ... ChemMedChem 14 (6), 686-698, 2019 | 3 | 2019 |
| What is chemical biology? AA Antolin, Y Aye, L Bar-Peled, E De Vita, N Dudkina, MC Jewett, ... Cell Chemical Biology 31 (9), 1562-1565, 2024 | | 2024 |
| Small Molecule KLK6 Inhibitors E De Vita Ruperto-Carola University Heidelberg, Germany, 2018 | | 2018 |
| Synthesis and inhibitory properties of carboxylate-based inhibitors and their fluorescence-labeled analogues with high affinity for some Metzincins. E DE VITA | | 2014 |
Edward W. TateImperial College London & Francis Crick InstituteVerified email at imperial.ac.uk